Education
About Us
Working with TipRanks
Follow Us
Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Total Valuation
Eris Lifesciences Ltd has a market cap or net worth of ₹240.94B. The enterprise value is ₹219.64B.
Market Cap₹240.94B
Enterprise Value₹219.64B
Share Statistics
Eris Lifesciences Ltd has 136,206,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding136,206,790
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eris Lifesciences Ltd’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 20.04%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)20.04%
Return on Capital Employed (ROCE)0.29
Revenue Per Employee7.95M
Profits Per Employee971.93K
Employee Count3,620
Asset Turnover0.41
Inventory Turnover2.13
Valuation Ratios
The current PE Ratio of Eris Lifesciences Ltd is 62.2. Eris Lifesciences Ltd’s PEG ratio is ―.
PE Ratio62.2
PS Ratio―
PB Ratio―
Price to Fair Value6.64
Price to FCF―
Price to Operating Cash Flow0.00
PEG Ratio―
Income Statement
In the last 12 months, Eris Lifesciences Ltd had revenue of 28.79B and earned 3.52B in profits. Earnings per share was 25.85.
Revenue28.79B
Gross Profit13.01B
Operating Income16.60B
Pretax Income4.89B
Net Income3.52B
EBITDA10.17B
Earnings Per Share (EPS)25.85
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Eris Lifesciences Ltd pays an annual dividend of ₹7.35, resulting in a dividend yield of 0.42%
Dividend Per Share₹7.35
Dividend Yield0.42%
Payout Ratio25.93%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.56
52-Week Price Change39.65%
50-Day Moving Average1.73K
200-Day Moving Average1.47K
Relative Strength Index (RSI)55.84
Average Volume (3m)4.89K
Important Dates
Eris Lifesciences Ltd upcoming earnings date is Nov 5, 2025, TBA (Confirmed).
Last Earnings DateAug 5, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend DateFeb 13, 2025
Financial Position
Eris Lifesciences Ltd as a current ratio of 0.89, with Debt / Equity ratio of 86.81%
Current Ratio0.89
Quick Ratio0.64
Debt to Market Cap0.13
Net Debt to EBITDA2.22
Interest Coverage Ratio7.18
Taxes
In the past 12 months, Eris Lifesciences Ltd has paid 1.14B in taxes.
Income Tax1.14B
Effective Tax Rate0.23
Enterprise Valuation
Eris Lifesciences Ltd EV to EBITDA ratio is 20.84, with an EV/FCF ratio of 23.30.
EV to Sales7.36
EV to EBITDA20.84
EV to Free Cash Flow23.30
EV to Operating Cash Flow19.91
Balance Sheet
Eris Lifesciences Ltd has ₹2.28B in cash and marketable securities with ₹24.78B in debt, giving a net cash position of ₹22.50B billion.
Cash & Marketable Securities₹2.28B
Total Debt₹24.78B
Net Cash₹22.50B
Net Cash Per Share₹165.20
Tangible Book Value Per Share-₹100.71
Margins
Gross margin is 60.89%, with operating margin of 57.66%, and net profit margin of 12.22%.
Gross Margin60.89%
Operating Margin57.66%
Pretax Margin16.98%
Net Profit Margin12.22%
EBITDA Margin35.33%
EBIT Margin24.37%
Analyst Forecast
The average price target for Eris Lifesciences Ltd is ₹1,926.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,926.00
Price Target Upside8.88% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast30.27%
EPS Growth Forecast1.69%